XBiotech (NASDAQ:XBIT) Shares Up 6.9%
XBiotech Inc (NASDAQ:XBIT) shot up 6.9% during trading on Friday . The company traded as high as $9.70 and last traded at $9.70, 205,300 shares were traded during mid-day trading. An increase of 27% from the average session volume of 161,513 shares. The stock had previously closed at $9.07.
A number of research firms have commented on XBIT. BidaskClub raised shares of XBiotech from a “hold” rating to a “buy” rating in a research report on Wednesday, August 21st. ValuEngine cut shares of XBiotech from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research reissued a “sell” rating on shares of XBiotech in a research report on Sunday, September 8th. Finally, Piper Jaffray Companies began coverage on shares of XBiotech in a research report on Friday, June 14th. They set an “overweight” rating and a $13.00 price target on the stock.
The firm has a market cap of $369.51 million, a price-to-earnings ratio of -16.44 and a beta of 0.41. The company’s 50-day moving average price is $7.91 and its 200-day moving average price is $8.56.
XBiotech Company Profile (NASDAQ:XBIT)
XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.
Further Reading: Initial Coin Offering (ICO)
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.